Scientific deep-dive

Does Mounjaro Cause Hair Loss? What the FDA Label Says (2026)

Mounjaro lists alopecia only as a postmarketing report, with no SURPASS trial rate. Why Zepbound's 5% doesn't transfer, and what to do about shedding.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
10 min read·12 citations

Mounjaro can be followed by hair shedding, but its FDA label does not give a rate for it: alopecia appears only in the postmarketing section, the list of reactions reported voluntarily after approval, where the label itself says frequency and cause cannot be reliably established.[1] The adverse-reaction table built from the SURPASS diabetes trials lists reactions seen in at least 5% of patients, and hair loss is not on it.[1] The 5% figure you may have seen online belongs to Zepbound, the same molecule studied for weight loss, and it does not transfer cleanly to people taking Mounjaro for type 2 diabetes.[2] This page covers what the Mounjaro label actually says, how much weight people lost in SURPASS, the diabetes-specific things that can thin hair alongside the drug, and what to do about it.

Short answer: hair loss on Mounjaro is possible and has been reported to the FDA since approval, but the diabetes trials did not produce a hair-loss number for the label. When it happens, it is most often the temporary shedding that follows weight loss (telogen effluvium). Do not stop Mounjaro on your own because of it: talk to your prescriber, who can check for other causes and adjust the pace of dose increases.

What the Mounjaro label says about hair loss

The current Mounjaro prescribing information on DailyMed mentions hair in exactly one place. Here is where it does and does not show up:[1]

Where hair loss appears in the Mounjaro (tirzepatide) label. Source: DailyMed, Mounjaro US prescribing information, read October 2026.
Label sectionWhat it coversHair loss?
§6.1 Table 1Adverse reactions in at least 5% of adults in two placebo-controlled trials (SURPASS-1 and SURPASS-5); 718 people on Mounjaro, mean exposure 36.6 weeksNot listed. The table shows nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia and abdominal pain
§6.1, seven-trial pool and CV outcomes trialBroader safety data across the SURPASS program and a cardiovascular trial in 6,647 adultsNot mentioned
§6.2 Postmarketing ExperienceReactions reported voluntarily after approval, from a population of uncertain sizeYes: “Skin and Subcutaneous Tissue: alopecia”, with no frequency

Two cautions about reading that table. First, “not in Table 1” means hair loss did not reach the 5% bar in those two trials, not that it never happened; the label simply does not report a lower-frequency figure. Second, a postmarketing listing is a signal, not a rate. It tells you enough people reported alopecia after taking Mounjaro for it to be added to the label, without telling you how often it happens or whether the drug, the weight loss, or something else caused it.[1]

Why Zepbound's 5% is not Mounjaro's number

The Zepbound label does report hair loss in its trial table: 5%, 4% and 5% of people on the 5 mg, 10 mg and 15 mg doses, against 1% on placebo, over up to 72 weeks. It adds that hair loss was “associated with weight reduction” and was far more common in women (7.1%) than men (0.5%) on the drug.[2] Same molecule, so why not apply that to Mounjaro? Three reasons:

  • Different goal, different trials. Zepbound's pool was built for weight loss: people with obesity or overweight treated for up to 72 weeks. Only 25% of them had type 2 diabetes.[2] Mounjaro's table comes from diabetes trials lasting 40 weeks, where the goal was blood sugar control.[1]
  • Different people. The Mounjaro pool averaged 58 years old and was 54% male; the Zepbound pool averaged 47 and was 37% male.[1][2] Because the Zepbound data show hair loss concentrated in women, a more male trial population would be expected to report less of it.
  • Less weight lost. People with type 2 diabetes tend to lose less weight on tirzepatide than people without it. In SURMOUNT-2, the Zepbound trial limited to adults with type 2 diabetes, the 72-week loss was 14.7% on 15 mg and 12.8% on 10 mg, compared with 20.9% on 15 mg in the trial without diabetes.[2][3] The SURPASS diabetes trials produced smaller losses still (below).

The Zepbound label does not break hair loss out for its participants with diabetes, so there is no published label rate for tirzepatide in type 2 diabetes alone. Our Zepbound hair loss page covers that weight-loss data in detail.

How much weight people lost in the SURPASS trials

Because weight-loss shedding tracks how much and how fast weight comes off, the SURPASS weight results are the most useful Mounjaro-specific data for this question. The label reports mean change in kilograms; the percentages below are our own arithmetic from those means and each group's starting weight.[1]

Mean body-weight change on Mounjaro in the SURPASS trials, from the Mounjaro label §14. Percent of starting weight is calculated from the label's mean kg change and mean baseline weight and is approximate.
Trial (length, comparator)5 mg10 mg15 mgComparator
SURPASS-1 (40 wk, placebo, no other diabetes drugs)−6.3 kg (~7%)−7.0 kg (~8%)−7.8 kg (~9%)−1.0 kg
SURPASS-2 (40 wk, semaglutide 1 mg, on metformin)−7.6 kg (~8%)−9.3 kg (~10%)−11.2 kg (~12%)−5.7 kg
SURPASS-3 (52 wk, insulin degludec)−7.0 kg (~7%)−9.6 kg (~10%)−11.3 kg (~12%)+1.9 kg
SURPASS-4 (52 wk, insulin glargine)−6.4 kg (~7%)−8.9 kg (~10%)−10.6 kg (~12%)+1.7 kg
SURPASS-5 (40 wk, placebo, on basal insulin)−5.4 kg (~6%)−7.5 kg (~8%)−8.8 kg (~9%)+1.6 kg

Magnitude comparison

Average weight lost on the top tirzepatide dose (15 mg), by trial. SURPASS figures are approximate percentages calculated from the Mounjaro label's mean kg change; SURMOUNT figures are the Zepbound label's reported percent change at 72 weeks.[1][2]

  • Mounjaro 15 mg, SURPASS-1 (40 wk)9.0 %
  • Mounjaro 15 mg, SURPASS-2 (40 wk)12.0 %
  • Mounjaro 15 mg, SURPASS-3 (52 wk)12.0 %
  • Zepbound 15 mg, SURMOUNT-2, with T2D (72 wk)14.7 %
  • Zepbound 15 mg, SURMOUNT-1, no T2D (72 wk)20.9 %
Average weight lost on the top tirzepatide dose (15 mg), by trial. SURPASS figures are approximate percentages calculated from the Mounjaro label's mean kg change; SURMOUNT figures are the Zepbound label's reported percent change at 72 weeks.

For scale: a Korean clinic that reviewed 140 people diagnosed with weight-loss shedding found they had lost an average of about 15% of their body weight, at roughly 3.5 kg a month.[4] The average SURPASS participant lost less than that and more slowly (the largest mean loss, 11.2 kg over 40 weeks, works out to a bit over 1 kg a month). Averages hide individuals, though. Someone who starts heavier, reaches 15 mg, or eats very little can lose much more, and the same study found women and older adults shed even at smaller losses.[4]

Note also that Mounjaro's label ties dose increases to blood sugar: the starting dose is 2.5 mg weekly, and it rises in 2.5 mg steps after at least 4 weeks only “if additional glycemic control is needed,” up to 15 mg.[1] Not everyone on Mounjaro ends up on the top dose.

Why the shedding happens

Most scalp hairs are growing at any moment (about 85%), with the rest resting before they fall out. A metabolic shock such as crash dieting, low protein intake or iron deficiency can push many growing hairs into the resting phase at once, and they shed together later. That pattern is called telogen effluvium: diffuse, non-scarring, and usually temporary.[5] The shedding typically shows up about 3 to 4 months after the trigger, which is why it can seem to come out of nowhere once your weight loss has already slowed.[6]

There is no established direct effect of tirzepatide on the hair follicle. The Zepbound label's own description, hair loss “associated with weight reduction,” fits the weight-loss explanation.[2] Across the class, a 2026 meta-analysis of seven randomized trials and two other interventional studies found hair loss about three times as likely on GLP-1 drugs as on placebo, with an overall event rate of 3.9%.[7] Real-world reporting for tirzepatide specifically is mixed: a 2026 meta-analysis that pooled adverse-event reporting databases found a tirzepatide alopecia signal, while a separate analysis of FDA reports from 2022 to 2025 found tirzepatide's signal was not significant.[8][9]

Diabetes-related causes worth ruling out

People taking Mounjaro for type 2 diabetes often have other things going on that can thin hair, and shedding is not proof the drug is to blame. A standard dermatology review notes that working out the cause of telogen effluvium means checking for endocrine, nutritional and autoimmune problems, not just pointing to the most recent change.[6] Points specific to people with diabetes:

  • Metformin and vitamin B12. Many people take Mounjaro on top of metformin (SURPASS-2 required it). The metformin label warns that it can lower B12: in 29-week trials about 7% of patients went from normal to below-normal B12, and it advises measuring B12 every 2 to 3 years.[10] Low B12 is not an established cause of telogen effluvium, but if you are due for that test, it can go in the same blood draw as the hair workup.
  • Iron and protein. Low iron and low protein intake are both listed triggers of telogen effluvium.[5] Mounjaro's most common side effects are appetite and digestive ones, with decreased appetite in up to 11% on 15 mg in the trial table, so smaller meals can quietly short both.[1] See our GLP-1 iron and ferritin guide.
  • Thyroid and other hormone problems. The review lists endocrine disorders among the causes to exclude.[6] A TSH blood test is the usual first check of thyroid function.
  • Other recent stressors. Severe infection, major surgery, and some medicines, including beta-blockers and anticoagulants that many people with diabetes and heart disease take, are known triggers of telogen effluvium.[5] Tell your clinician what else changed in the 3 to 4 months before the shedding began.

What to do if your hair is shedding on Mounjaro

  1. Keep taking it and call your prescriber. Mounjaro is treating your diabetes, and the label lowered A1c by roughly 1.7 to 2.4 points across the SURPASS trials.[1] Stopping it suddenly gives that up for a problem that is usually temporary.
  2. Ask about the pace of dose increases. Because dose steps are tied to blood-sugar needs, your prescriber may be able to stay at your current dose for longer if your A1c is on target.[1]
  3. Ask for blood work. Ferritin and a blood count for iron, TSH for thyroid, and B12 if you take metformin.[6][10]
  4. Protect your protein intake. Build each smaller meal around a protein source, since low protein intake is a recognized trigger.[5] A dietitian can set a target that fits your diabetes plan.
  5. Skip high-dose biotin. A review of the evidence found no good support for biotin in people who are not deficient.[11] High-dose biotin can also distort some thyroid (TSH) and troponin lab tests, so tell the lab if you take it.[12]
  6. Give it months, not weeks. Telogen effluvium usually settles once the trigger passes. If you want to try a treatment such as minoxidil, see our minoxidil and finasteride evidence review and ask a dermatologist first.

When to see a dermatologist

Weight-loss shedding is spread evenly over the scalp and leaves no scars.[5] Get a dermatology appointment rather than waiting it out if you notice:

  • round or patchy bald spots instead of even thinning;
  • redness, scaling, pain, itching, or smooth shiny patches where hair is gone;
  • a receding hairline, widening part, or thinning crown that follows a pattern;
  • shedding that is still heavy several months after your weight has leveled off.

For the same question on the other brands, see GLP-1 hair loss, Ozempic, Wegovy and semaglutide. For the brand difference itself, see Mounjaro vs Zepbound and the Mounjaro drug page.

Our reviews

Providers that offer tirzepatide

Telehealth providers we’ve reviewed. Each opens our full, independent review.

We may earn a commission from featured partners. Learn more

See the full ranking →

Frequently Asked Questions

It can be followed by hair loss, but the Mounjaro label gives no rate for it. Alopecia appears only in the label's postmarketing section, meaning it was reported after approval, and it is not in the table of reactions seen in at least 5% of people in the SURPASS diabetes trials. When shedding happens it is usually telogen effluvium linked to weight loss, which is temporary.
It is the same molecule, tirzepatide, and the same kind of shedding. But the 5% hair-loss figure belongs to the Zepbound label, from weight-loss trials of up to 72 weeks in mostly younger, mostly female participants. Mounjaro's diabetes trials were shorter, enrolled older and more male participants, and produced less weight loss, and the Mounjaro label reports no comparable rate.
Not on your own. Mounjaro is controlling your blood sugar, and weight-loss shedding usually settles by itself. Talk to your prescriber, who can check for other causes such as low iron, thyroid problems, or low B12 if you take metformin, and may be able to slow dose increases if your A1c is on target.
Telogen effluvium typically appears about 3 to 4 months after the trigger, so people often notice it a few months into treatment, sometimes after their weight loss has already slowed.
In most cases, yes. Weight-loss shedding is non-scarring and usually resolves once the trigger passes and nutrition is adequate. Patchy, scarring, painful, or pattern-shaped loss, or shedding that persists for months after your weight stabilizes, should be checked by a dermatologist.
There is no direct evidence of that. Metformin can lower vitamin B12, and its label advises checking B12 every 2 to 3 years. B12 is not an established cause of telogen effluvium, but if you are due for the test it is easy to add to a hair-loss blood panel.

References

  1. 1.Eli Lilly and Company MOUNJARO (tirzepatide) injection, for subcutaneous use. US Prescribing Information: §2.1 Recommended Dosage, §6.1 Clinical Trials Experience, §6.2 Postmarketing Experience (alopecia), §14 Clinical Studies (SURPASS-1 to -5). DailyMed (NIH/NLM). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
  2. 2.Eli Lilly and Company ZEPBOUND (tirzepatide) injection, for subcutaneous use. US Prescribing Information: §6.1 Table 1 (hair loss) and Hair Loss subsection; §14 Clinical Studies (Studies 1 and 2). DailyMed (NIH/NLM). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  3. 3.Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, et al.; SURMOUNT-2 investigators Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023. PMID: 37385275.
  4. 4.Kang DH, Kwon SH, Sim WY, Lew BL Telogen Effluvium Associated With Weight Loss: A Single Center Retrospective Study. Ann Dermatol. 2024. PMID: 39623615.
  5. 5.Hughes EC, Syed HA, Saleh D Telogen Effluvium. StatPearls Publishing. 2024. PMID: 28613598.
  6. 6.Malkud S Telogen Effluvium: A Review. J Clin Diagn Res. 2015. PMID: 26500992.
  7. 7.Cheng PL, Chang HC Glucagon-like peptide-1 receptor agonists and hair loss: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2026. PMID: 42155605.
  8. 8.Viquez Burboa GU, Flores Guillén MÁR, Duardo González VS GLP-1 Receptor Agonists and Alopecia: A Systematic Review and Meta-Analysis of Incidence, Risk, Subtypes, and Mechanisms. Skin Appendage Disord. 2026. PMID: 42621629.
  9. 9.Lee N, Kim Y Not All GLP-1 Receptor Agonists Are Alike: Real-World Evidence of Differential Endocrine and Dermatologic Safety. Diabetes Metab Res Rev. 2026. PMID: 41886296.
  10. 10.U.S. National Library of Medicine Metformin hydrochloride tablets. US Prescribing Information: §5.2 Vitamin B12 Deficiency. DailyMed (NIH/NLM). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f86bda10-8b25-4125-8bb1-1b5917969ff0
  11. 11.Patel DP, Swink SM, Castelo-Soccio L A Review of the Use of Biotin for Hair Loss. Skin Appendage Disord. 2017. PMID: 28879195.
  12. 12.Mzougui S, Favresse J, Soleimani R, Fillée C, Gruson D Biotin interference: evaluation of a new generation of electrochemiluminescent immunoassays for high-sensitive troponin T and thyroid-stimulating hormone testing. Clin Chem Lab Med. 2020. PMID: 32324155.

Zepbound Hair Loss: How to Stop It and What the Label Says (2026)

Zepbound's label lists hair loss in 4–5% of users vs 1% on placebo, mostly women. How to stop it, why a lower dose may not help, and when to see a doctor.

11 min read

Ozempic Hair Loss: What the Label and Diabetes Data Show (2026)

Ozempic's label lists hair loss only in postmarketing reports. What a 2026 type 2 diabetes study found, why Wegovy's rate is higher, and when to see a doctor.

10 min read

Do GLP-1s Cause Hair Loss? What All 5 Labels Say (2026)

Wegovy and Zepbound list hair loss in 3–6% of adults vs 1% on placebo; Ozempic, Rybelsus and Mounjaro give no rate. Why it happens and what helps.

8 min read

Does Semaglutide Cause Hair Loss? Ozempic vs Wegovy (2026)

Only Wegovy's label prints a semaglutide hair-loss rate (3.3% vs 1%). What Ozempic, Rybelsus and compounded semaglutide labels say, and what helps.

10 min read

GLP-1 + Finasteride or Minoxidil for Hair Loss: The Stacking Guide

GLP-1 telogen effluvium is real — 10-15% of patients shed during rapid weight loss. Stacking with finasteride 1 mg or topical minoxidil 5% can rescue regrowth. We review the published TE trials, finasteride PROPECIA pivotal, and the practical 6-month protocol.

12 min read

GLP-1 Side Effects Duration: Fatigue, Hair Loss, and How Long Everything Actually Lasts

Most GLP-1 nausea fades within 1 to 2 weeks at each dose step, peaking in the first 1 to 2 weeks after an increase. Fatigue was reported by about 11% on semaglutide versus 5% on placebo in the Wegovy label's pooled STEP 1-3 data. This guide covers how long fatigue, hair loss, and GI effects last.

11 min read

Where to get tirzepatide (Mounjaro / Zepbound) safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

7.8

Embody

Low flat-rate compounded GLP-1 pricing at every dose

Read full review →

From $129/mo

sale price

Get started →
8.2

Gala

Compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping

Read full review →

From $179/mo

prepaid plan rate

Get started →
8.3

Found

Medication-included compounded GLP-1 on 28-day cash plans, plus insurance help for brand-name GLP-1s

Read full review →

From $239/mo

12-month plan rate

Get started →

About this analysis

Weight Loss Rankings is an independent editorial publication. Our provider dataset is verified directly against each provider's website and updated continuously. Read our full methodology →